Enhancing nanomedicine development through collaboration

CPI is part of a collaborative project strengthening its nanoformulations capabilities. The project aims to evaluate a new microfluidic-based platform for the scale-up, process development and manufacture of nanoformulated medicines.

CPI is leading the consortium to build capability to support the development of new nanotherapeutic products and technologies emerging from academia and the biotech sector, for clinical evaluation and commercialisation. Nanotherapeutic delivery systems have the potential to transform the delivery of pharmaceutical modalities such as nucleic acids, gene therapies and peptide based medicines and include lipid nanoparticles, liposomes, polymeric micelles, polymeric nanoparticles and inorganic nanoparticles, which enable targeted drug delivery, intracellular delivery and trafficking, extend drug half-life, improve a drug’s therapeutic index, and reduce a drug’s immunogenicity. However, the development of robust and scalable processes for nanomedicines manufacture remains a challenge, with poor manufacturability being a potential barrier to commercial success for the next generation of nanotherapeutics. Click here to read more